全文获取类型
收费全文 | 489篇 |
免费 | 38篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 4篇 |
妇产科学 | 11篇 |
基础医学 | 71篇 |
口腔科学 | 30篇 |
临床医学 | 36篇 |
内科学 | 77篇 |
皮肤病学 | 10篇 |
神经病学 | 45篇 |
特种医学 | 11篇 |
外科学 | 119篇 |
综合类 | 3篇 |
预防医学 | 10篇 |
眼科学 | 13篇 |
药学 | 38篇 |
肿瘤学 | 49篇 |
出版年
2022年 | 4篇 |
2021年 | 6篇 |
2020年 | 9篇 |
2019年 | 6篇 |
2018年 | 9篇 |
2017年 | 8篇 |
2016年 | 11篇 |
2015年 | 5篇 |
2014年 | 13篇 |
2013年 | 15篇 |
2012年 | 20篇 |
2011年 | 19篇 |
2010年 | 4篇 |
2009年 | 10篇 |
2008年 | 16篇 |
2007年 | 19篇 |
2006年 | 17篇 |
2005年 | 34篇 |
2004年 | 31篇 |
2003年 | 31篇 |
2002年 | 25篇 |
2001年 | 15篇 |
2000年 | 24篇 |
1999年 | 31篇 |
1998年 | 8篇 |
1997年 | 4篇 |
1993年 | 4篇 |
1992年 | 10篇 |
1991年 | 4篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 6篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 8篇 |
1984年 | 4篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1976年 | 3篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1972年 | 5篇 |
1971年 | 5篇 |
1969年 | 3篇 |
1968年 | 3篇 |
1967年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有528条查询结果,搜索用时 31 毫秒
1.
Wilches-Buitrago L. Viacava P. R. Cunha F. Q. Alves-Filho J. C. Fukada S. Y. 《Inflammation research》2019,68(5):415-421
Inflammation Research - Although some glycolytic intermediates have been shown to modulate several cell type formation and activation, the functional role of fructose 1,6-bisphosphate (FBP) on... 相似文献
2.
3.
4.
5.
Takahito Ito Ryo Ogawa Akiyoshi Uezumi Takuji Ohtani Yoko Watanabe Kazutake Tsujikawa Yuko Miyagoe-Suzuki Shin’ichi Takeda Hiroshi Yamamoto So-ichiro Fukada 《Neuromuscular disorders : NMD》2013,23(4):349-356
Imatinib mesylate inhibits signaling of tyrosine kinase receptors, including PDGFRα, and has been used for human cancer therapy. Recent studies have indicated that imatinib is also effective in treatment of some chronic diseases with fibrosis. Fibrosis is the feature of Duchenne muscular dystrophy. It has been reported that imatinib attenuates fibrosis in mdx mice. Recently we revealed that PDGFRα is specifically expressed in muscle mesenchymal progenitors, which are the origin of muscle fibrosis. Here, we show that imatinib ameliorates the muscular pathology of DBA/2-mdx, a more severe mouse muscular dystrophy. In addition, imatinib inhibits both the proliferation and fibrosis marker expression induced by PDGF-AA in muscle mesenchymal progenitors in vitro. Importantly, the effective dose of imatinib on muscle mesenchymal progenitors did not inhibit myoblast proliferation. These results suggest that imatinib targets mesenchymal progenitors, and that a therapeutic strategy targeting mesenchymal progenitors could be a potential treatment for muscular dystrophies. 相似文献
6.
Adriana L. Carvalho Bianca Massaro Luciana T. P. e Silva Carlos E.G. Salmon Sandra Y. Fukada Marcello H. Nogueira-Barbosa Jorge Elias Maria C.F. Freitas Carlos E.B. Couri Maria C. Oliveira Belinda P. Simões Clifford J. Rosen Francisco J.A. de Paula 《Journal of clinical densitometry》2019,22(3):420-428
Anthropomorphic measures among type 1 diabetic patients are changing as the obesity epidemic continues. Excess fat mass may impact bone density and ultimately fracture risk. We studied the interaction between bone and adipose tissue in type 1 diabetes subjects submitted to two different clinical managements: (I) conventional insulin therapy or (II) autologous nonmyeloablative hematopoietic stem-cell transplantation (AHST). The study comprised 3 groups matched by age, gender, height and weight: control (C = 24), type 1 diabetes (T1D = 23) and type 1 diabetes treated with AHST (T1D-AHST = 9). Bone mineral density (BMD) and trabecular bone score (TBS) were assessed by dual X-ray absorptiometry (DXA). 1H Magnetic resonance spectroscopy was used to assess bone marrow adipose tissue (BMAT) in the L3 vertebra, and abdominal magnetic resonance imaging was used to assess intrahepatic lipids (IHL), visceral (VAT) and subcutaneous adipose tissue (SAT). Individuals conventionally treated for T1D were more likely to be overweight (C = 23.8 ± 3.7; T1D = 25.3 ± 3.4; T1D-AHST = 22.5 ± 2.2 Kg/m2; p > 0.05), but there was no excessive lipid accumulation in VAT or liver. Areal BMD of the three groups were similar at all sites; lumbar spine TBS (L3) was lower in type 1 diabetes (p < 0.05). Neither SAT nor VAT had any association with bone parameters. Bone marrow adipose tissue (BMAT) lipid profiles were similar among groups. BMAT saturated lipids were associated with cholesterol, whereas unsaturated lipids had an association with IGF1. Overweight and normal weight subjects with type 1 diabetes have normal areal bone density, but lower trabecular bone scores. Adipose distribution is normal and BMAT volume is similar to controls, irrespective of clinical treatment. 相似文献
7.
8.
9.
10.
Sotaro Sadahiro Toshiyuki Suzuki Akira Tanaka Kazutake Okada Hiroko Kamata Jun Koisumi 《Surgery today》2013,43(10):1088-1094
The most common site of metastases in patients with colorectal cancer is the liver. Hepatic resection is considered to be the treatment of choice for liver metastasis from colorectal cancer; however, hepatic resection can be performed in only 20 or 25 % of all patients. Recurrence develops in the remnant liver or other organs after hepatic resection in over half of all patients with liver-only metastasis. Hepatic arterial infusion (HAI) chemotherapy can provide relatively high concentrations of drugs to microscopic or macroscopic metastases in the liver, with less toxicity than systemic administration. Meta-analyses have shown HAI chemotherapy to have a significantly higher response rate than systemic chemotherapy and its effect on extrahepatic metastases is negligible. HAI chemotherapy provides much better local control of liver metastases from colorectal cancer than systemic chemotherapy. However, well-controlled studies are needed to elucidate the optimal treatment strategies for neoadjuvant and postoperative adjuvant chemotherapy that optimally combine HAI chemotherapy, molecular targeted agents, and systemic chemotherapy such as FOLFOX or FOLFIRI. 相似文献